Intravenous delivery unlocks multi-tissue genetic medicine
The thesis presented was that moving genetic medicine beyond local tumor injections into systemic intravenous administration overcomes structural drug-delivery bottlenecks to access visceral metastases and scale population-level cancer treatments.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.